Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Lang, S; Zeidler, R; Pauli, C; Andratschke, M; Wollenberg, B
   Targeting head and neck cancer by IL-2-mediated gene therapy: From bench to bedside - A review.
   LARYNGO-RHINO-OTOLOGIE
   
   S. Lang et al., "Targeting head and neck cancer by IL-2-mediated gene therapy: From bench to bedside - A review.", LARY RH OTO, 80(4), 2001, pp. 191-195
2. Pappo, I; Lotem, M; Klein, M; Orda, R
   Bolus high dose interleukin-2 for the treatment of malignant melanoma
   ISRAEL MEDICAL ASSOCIATION JOURNAL
   
   I. Pappo et al., "Bolus high dose interleukin-2 for the treatment of malignant melanoma", ISR MED ASS, 3(3), 2001, pp. 169-173
3. Ohteki, T; Suzue, K; Maki, C; Ota, T; Koyasu, S
   Critical role of IL-15-IL-15R for antigen-presenting cell functions in theinnate immune response
   NATURE IMMUNOLOGY
   
   T. Ohteki et al., "Critical role of IL-15-IL-15R for antigen-presenting cell functions in theinnate immune response", NAT IMMUNOL, 2(12), 2001, pp. 1138-1143
4. Grasso, M; Torelli, F; Scannapieco, G; Franzoso, F; Lania, C
   Neoadiuvant treatment with intravesical interleukin-2 for recurrent superficial transitional bladder carcinoma Ta-T1/G1-2
   JOURNAL OF IMMUNOTHERAPY
   
   M. Grasso et al., "Neoadiuvant treatment with intravesical interleukin-2 for recurrent superficial transitional bladder carcinoma Ta-T1/G1-2", J IMMUNOTH, 24(2), 2001, pp. 184-187
5. Bankert, RB; Egilmez, NK; Hess, SD
   Human-SCID mouse chimeric models for the evaluation of anti-cancer therapies
   TRENDS IN IMMUNOLOGY
   
   R.B. Bankert et al., "Human-SCID mouse chimeric models for the evaluation of anti-cancer therapies", TRENDS IMMU, 22(7), 2001, pp. 386-393
6. Atkins, MB; Dutcher, J; Weiss, G; Margolin, K; Clark, J; Sosman, J; Logan, T; Aronson, F; Mier, J
   Kidney cancer: The Cytokine Working Group experience (1986-2001) - Part I.IL-2-based clinical trials
   MEDICAL ONCOLOGY
   
   M.B. Atkins et al., "Kidney cancer: The Cytokine Working Group experience (1986-2001) - Part I.IL-2-based clinical trials", MED ONCOL, 18(3), 2001, pp. 197-207
7. Dutcher, J; Atkins, MB; Margolin, K; Weiss, G; Clark, J; Sosman, J; Logan, T; Aronson, F; Mier, J
   Kidney cancer: The Cytokine Working Group experience (1986-2001) - Part II: Management of IL-2 toxicity and studies with other cytokines
   MEDICAL ONCOLOGY
   
   J. Dutcher et al., "Kidney cancer: The Cytokine Working Group experience (1986-2001) - Part II: Management of IL-2 toxicity and studies with other cytokines", MED ONCOL, 18(3), 2001, pp. 209-219
8. van West, D; Maes, M
   Neuroendocrine and immune aspects of fibromyalgia
   BIODRUGS
   
   D. van West e M. Maes, "Neuroendocrine and immune aspects of fibromyalgia", BIODRUGS, 15(8), 2001, pp. 521-531
9. Alvarnas, JC; Linn, YC; Hope, EG; Negrin, RS
   Expansion of cytotoxic CD3(+)CD56(+) cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation
   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
   
   J.C. Alvarnas et al., "Expansion of cytotoxic CD3(+)CD56(+) cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation", BIOL BLOOD, 7(4), 2001, pp. 216-222
10. Buzaid, AC; Atkins, M
    Practical guidelines for the management of biochemotherapy-related toxicity in melanoma
    CLINICAL CANCER RESEARCH
    
    A.C. Buzaid e M. Atkins, "Practical guidelines for the management of biochemotherapy-related toxicity in melanoma", CLIN CANC R, 7(9), 2001, pp. 2611-2619
11. Holden, SA; Lan, Y; Pardo, AM; Wesolowski, JS; Gillies, SD
    Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents
    CLINICAL CANCER RESEARCH
    
    S.A. Holden et al., "Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents", CLIN CANC R, 7(9), 2001, pp. 2862-2869
12. Waldmann, TA; Dubois, S; Tagaya, Y
    Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: Implications for immunotherapy
    IMMUNITY
    
    T.A. Waldmann et al., "Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: Implications for immunotherapy", IMMUNITY, 14(2), 2001, pp. 105-110
13. Airoldi, M; De Stefani, A; Marchionatti, S; Pedani, F; Gabriele, P; Ragona, R; Cortesina, G; Bumma, C
    Survival in patients with recurrent squamous cell head and neck carcinoma treated with bio-chemotherapy
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
    
    M. Airoldi et al., "Survival in patients with recurrent squamous cell head and neck carcinoma treated with bio-chemotherapy", HEAD NECK, 23(4), 2001, pp. 298-304
14. Kaufman, HL; DeRaffele, G; Divito, J; Horig, H; Lee, D; Panicali, D; Voulo, M
    A phase I trial of intralesional rV-Tricom vaccine in the treatment of malignant melanoma
    HUMAN GENE THERAPY
    
    H.L. Kaufman et al., "A phase I trial of intralesional rV-Tricom vaccine in the treatment of malignant melanoma", HUM GENE TH, 12(11), 2001, pp. 1459-1480
15. Huang, YW; Hayes, RL; Wertheim, S; Arbit, E; Scheff, R
    Treatment of refractory recurrent malignant glioma with adoptive cellular immunotherapy: a case report
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
    
    Y.W. Huang et al., "Treatment of refractory recurrent malignant glioma with adoptive cellular immunotherapy: a case report", CR R ONC H, 39(1-2), 2001, pp. 17-23
16. Hayes, RL; Arbit, E; Odaimi, M; Pannullo, S; Scheff, R; Kravchinskiy, D; Zaroulis, C
    Adoptive cellular immunotherapy for the treatment of malignant gliomas
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
    
    R.L. Hayes et al., "Adoptive cellular immunotherapy for the treatment of malignant gliomas", CR R ONC H, 39(1-2), 2001, pp. 31-42
17. Cohen, PA; Peng, LM; Kjaergaard, J; Plautz, GE; Finke, JH; Koski, GK; Czerniecki, BJ; Shu, SY
    T-cell adoptive therapy of tumors: Mechanisms of improved therapeutic performance
    CRITICAL REVIEWS IN IMMUNOLOGY
    
    P.A. Cohen et al., "T-cell adoptive therapy of tumors: Mechanisms of improved therapeutic performance", CR R IMMUN, 21(1-3), 2001, pp. 215-248
18. Minami, K; Yamaguchi, Y; Yoshida, K; Quan, CP; Toge, T
    Dysregulation of telomerase activity and expression in lymphokine-activated killer cells from advanced cancer patients: Possible involvement in cancer-associated immunosuppression mechanism
    ONCOLOGY REPORTS
    
    K. Minami et al., "Dysregulation of telomerase activity and expression in lymphokine-activated killer cells from advanced cancer patients: Possible involvement in cancer-associated immunosuppression mechanism", ONCOL REP, 8(3), 2001, pp. 649-653
19. Rosenberg, SA
    Progress in the development of immunotherapy for the treatment of patientswith cancer
    JOURNAL OF INTERNAL MEDICINE
    
    S.A. Rosenberg, "Progress in the development of immunotherapy for the treatment of patientswith cancer", J INTERN M, 250(6), 2001, pp. 462-475
20. Phan, GQ; Attia, P; Steinberg, SM; White, DE; Rosenberg, SA
    Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma
    JOURNAL OF CLINICAL ONCOLOGY
    
    G.Q. Phan et al., "Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma", J CL ONCOL, 19(15), 2001, pp. 3477-3482
21. Heinzer, H; Huland, E; Huland, H
    Systemic chemotherapy and chemoimmunotherapy for metastatic renal cell cancer
    WORLD JOURNAL OF UROLOGY
    
    H. Heinzer et al., "Systemic chemotherapy and chemoimmunotherapy for metastatic renal cell cancer", WORLD J URO, 19(2), 2001, pp. 111-119
22. Kobayashi, H; Tanaka, Y; Yagi, J; Toma, H; Uchiyama, T
    Gamma/delta T cells provide innate immunity against renal cell carcinoma
    CANCER IMMUNOLOGY IMMUNOTHERAPY
    
    H. Kobayashi et al., "Gamma/delta T cells provide innate immunity against renal cell carcinoma", CANCER IMMU, 50(3), 2001, pp. 115-124
23. He, L; Feng, HP; Raymond, A; Kreeger, M; Zeng, Y; Graner, M; Whitesell, L; Katsanis, E
    Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice
    CANCER IMMUNOLOGY IMMUNOTHERAPY
    
    L. He et al., "Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice", CANCER IMMU, 50(1), 2001, pp. 31-40
24. Al-Atrash, G; Kitson, RP; Xue, YM; Mazar, AP; Kim, MH; Goldfarb, RH
    uPA and uPAR contribute to NK cell invasion through the extracellular matrix
    ANTICANCER RESEARCH
    
    G. Al-Atrash et al., "uPA and uPAR contribute to NK cell invasion through the extracellular matrix", ANTICANC R, 21(3B), 2001, pp. 1697-1704
25. Yamaguchi, Y; Ohta, K; Shimizu, K; Minami, K; Noma, K; Hihara, J; Toge, T
    Generation of cytotoxic effector lymphocytes by MLTC using tumor cells genetically modified to secrete interleukin-2
    ANTICANCER RESEARCH
    
    Y. Yamaguchi et al., "Generation of cytotoxic effector lymphocytes by MLTC using tumor cells genetically modified to secrete interleukin-2", ANTICANC R, 21(1B), 2001, pp. 669-677
26. Lathers, DMR; Clark, JI; Achille, NJ; Young, MRI
    Phase IB study of 25-hydroxyvitamin D-3 treatment to diminish suppressor cells in head and neck cancer patients
    HUMAN IMMUNOLOGY
    
    D.M.R. Lathers et al., "Phase IB study of 25-hydroxyvitamin D-3 treatment to diminish suppressor cells in head and neck cancer patients", HUMAN IMMUN, 62(11), 2001, pp. 1282-1293
27. Stassar, MJJG; Raddrizzani, L; Hammer, J; Zoller, M
    T-helper cell-response to MHC class II-binding peptides of the renal cell carcinoma-associated antigen RAGE-1
    IMMUNOBIOLOGY
    
    M.J.J.G. Stassar et al., "T-helper cell-response to MHC class II-binding peptides of the renal cell carcinoma-associated antigen RAGE-1", IMMUNOBIOL, 203(5), 2001, pp. 743-755
28. Wroblewski, JM; Bixby, DL; Borowski, C; Yannelli, JR
    Characterization of human non-small cell lung cancer (NSCLC) cell lines for expression of MHC, co-stimulatory molecules and tumor-associated antigens
    LUNG CANCER
    
    J.M. Wroblewski et al., "Characterization of human non-small cell lung cancer (NSCLC) cell lines for expression of MHC, co-stimulatory molecules and tumor-associated antigens", LUNG CANC, 33(2-3), 2001, pp. 181-194
29. Castagneto, B; Zai, S; Mutti, L; Lazzaro, A; Ridolfi, R; Piccolini, E; Ardizzoni, A; Fumagalli, L; Valsuani, G; Botta, M
    Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion - Results of a phase II study on 31 consecutive patients
    LUNG CANCER
    
    B. Castagneto et al., "Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion - Results of a phase II study on 31 consecutive patients", LUNG CANC, 31(2-3), 2001, pp. 303-310
30. Bellinger, DL; Felten, DL; Lorton, D; Brouxhon, S
    Effects of interleukin-2 on the expression of corticotropin-releasing hormone in nerves and lymphoid cells in secondary lymphoid organs from the Fischer 344 rat
    JOURNAL OF NEUROIMMUNOLOGY
    
    D.L. Bellinger et al., "Effects of interleukin-2 on the expression of corticotropin-releasing hormone in nerves and lymphoid cells in secondary lymphoid organs from the Fischer 344 rat", J NEUROIMM, 119(1), 2001, pp. 37-50
31. Li, GX; Lillehoj, HS; Min, WG
    Production and characterization of monoclonal antibodies reactive with thechicken interleukin-15 receptor alpha chain
    VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY
    
    G.X. Li et al., "Production and characterization of monoclonal antibodies reactive with thechicken interleukin-15 receptor alpha chain", VET IMMUNOL, 82(3-4), 2001, pp. 215-227
32. Lillehoj, HS; Min, WG; Choi, KD; Babu, US; Bumside, J; Miyamoto, T; Rosenthal, BM; Lillehoj, EP
    Molecular, cellular, and functional characterization of chicken cytokines homologous to mammalian IL-15 and IL-2
    VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY
    
    H.S. Lillehoj et al., "Molecular, cellular, and functional characterization of chicken cytokines homologous to mammalian IL-15 and IL-2", VET IMMUNOL, 82(3-4), 2001, pp. 229-244
33. Kintzel, PE
    Anticancer drug-induced kidney disorders - Incidence, prevention and management
    DRUG SAFETY
    
    P.E. Kintzel, "Anticancer drug-induced kidney disorders - Incidence, prevention and management", DRUG SAFETY, 24(1), 2001, pp. 19-38
34. Mieijer, SL; Dols, A; Hu, HM; Jensen, S; Poehlein, CH; Chu, Y; Winter, H; Yamada, J; Moudgil, T; Wood, WJ; Doran, T; Justice, L; Fisher, B; Wisner, P; Wood, J; Vetto, JT; Mehrotra, R; Rosenheim, S; Weinberg, AD; Bright, R; Walker, E; Puri, R; Smith, JW; Urba, WJ; Fox, BA
    Immunological and molecular analysis of the sentinel lymph node: A potential approach to predict outcome, tailor therapy, and optimize parameters fortumor vaccine development
    JOURNAL OF CLINICAL PHARMACOLOGY
    
    S.L. Mieijer et al., "Immunological and molecular analysis of the sentinel lymph node: A potential approach to predict outcome, tailor therapy, and optimize parameters fortumor vaccine development", J CLIN PHAR, 2001, pp. 81S-94S
35. Clarke, R; Leonessa, F; Welch, JN; Skaar, TC
    Cellular and molecular pharmacology of antiestrogen action and resistance
    PHARMACOLOGICAL REVIEWS
    
    R. Clarke et al., "Cellular and molecular pharmacology of antiestrogen action and resistance", PHARM REV, 53(1), 2001, pp. 25-71
36. Malaguarnera, M; Ferlito, L; Gulizia, G; Di Fazio, I; Pistone, G
    Use of interleukin-2 in advanced renal carcinoma: meta-analysis and reviewof the literature
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    
    M. Malaguarnera et al., "Use of interleukin-2 in advanced renal carcinoma: meta-analysis and reviewof the literature", EUR J CL PH, 57(4), 2001, pp. 267-273
37. Elias, L; Hunt, WC
    A literature analysis of prognostic factors for response and quality of response of patients with renal cell carcinoma to interleukin-2-based therapy
    ONCOLOGY
    
    L. Elias e W.C. Hunt, "A literature analysis of prognostic factors for response and quality of response of patients with renal cell carcinoma to interleukin-2-based therapy", ONCOL-BASEL, 61(2), 2001, pp. 91-101
38. Chi, KH; Myers, JN; Chow, KC; Chan, WK; Tsang, YW; Chao, Y; Yen, SH
    Phase II trial of systemic recombinant interleukin-2 in the treatment of refractory nasopharyngeal carcinoma
    ONCOLOGY
    
    K.H. Chi et al., "Phase II trial of systemic recombinant interleukin-2 in the treatment of refractory nasopharyngeal carcinoma", ONCOL-BASEL, 60(2), 2001, pp. 110-115
39. Flanigan, RC; Salmon, SE; Blumenstein, BA; Bearman, SI; Roy, V; McGrath, PC; Caton, JR; Munshi, N; Crawford, ED
    Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer
    NEW ENGLAND JOURNAL OF MEDICINE
    
    R.C. Flanigan et al., "Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer", N ENG J MED, 345(23), 2001, pp. 1655-1659
40. Rosenberg, SA
    Progress in human tumour immunology and immunotherapy
    NATURE
    
    S.A. Rosenberg, "Progress in human tumour immunology and immunotherapy", NATURE, 411(6835), 2001, pp. 380-384
41. Deshmukh, P; Glick, RP; Lichtor, T; Moser, R; Cohen, EP
    Immunogene therapy with interleukin-2-secreting fibroblasts for intracerebrally metastasizing breast cancer in mice
    JOURNAL OF NEUROSURGERY
    
    P. Deshmukh et al., "Immunogene therapy with interleukin-2-secreting fibroblasts for intracerebrally metastasizing breast cancer in mice", J NEUROSURG, 94(2), 2001, pp. 287-292
42. Bulanova, E; Budagian, V; Pohl, T; Krause, H; Durkop, H; Paus, R; Bulfone-Paus, S
    The IL-15R alpha chain signals through association with Syk in human B cells
    JOURNAL OF IMMUNOLOGY
    
    E. Bulanova et al., "The IL-15R alpha chain signals through association with Syk in human B cells", J IMMUNOL, 167(11), 2001, pp. 6292-6302
43. Abe, Y; Matsumoto, S; Wei, SM; Nezu, K; Miyoshi, A; Kito, K; Ueda, N; Shigemoto, K; Hitsumoto, Y; Nikawa, J
    Cloning and characterization of a p53-related protein kinase expressed in interleukin-2-activated cytotoxic T-cells, epithelial tumor cell lines, andthe testes
    JOURNAL OF BIOLOGICAL CHEMISTRY
    
    Y. Abe et al., "Cloning and characterization of a p53-related protein kinase expressed in interleukin-2-activated cytotoxic T-cells, epithelial tumor cell lines, andthe testes", J BIOL CHEM, 276(47), 2001, pp. 44003-44011
44. Nishiyama, R; Sakaguchi, T; Kinugasa, T; Gu, XB; MacDermott, RP; Podolsky, DK; Reinecker, HC
    Interleukin-2 receptor beta subunit-dependent and -independent regulation of intestinal epithelial tight junctions
    JOURNAL OF BIOLOGICAL CHEMISTRY
    
    R. Nishiyama et al., "Interleukin-2 receptor beta subunit-dependent and -independent regulation of intestinal epithelial tight junctions", J BIOL CHEM, 276(38), 2001, pp. 35571-35580
45. Masuda, A; Matsuguchi, T; Yamaki, K; Hayakawa, T; Yoshikai, Y
    Interleukin-15 prevents mouse mast cell apoptosis through STAT6-mediated Bcl-x(L) expression
    JOURNAL OF BIOLOGICAL CHEMISTRY
    
    A. Masuda et al., "Interleukin-15 prevents mouse mast cell apoptosis through STAT6-mediated Bcl-x(L) expression", J BIOL CHEM, 276(28), 2001, pp. 26107-26113
46. Sekine, K; Fujii, H; Abe, F; Nishikawa, K
    Augmentation of death ligand-induced apoptosis by aminopeptidase inhibitors in human solid tumor cell lines
    INTERNATIONAL JOURNAL OF CANCER
    
    K. Sekine et al., "Augmentation of death ligand-induced apoptosis by aminopeptidase inhibitors in human solid tumor cell lines", INT J CANC, 94(4), 2001, pp. 485-491
47. Pizza, G; De Vinci, C; Lo Conte, G; Maver, P; Dragoni, E; Aiello, E; Fornarola, V; Bergami, T; Busutti, L; Boriani, S; Palareti, A; Capanna, R
    Immunotherapy of metastatic kidney cancer
    INTERNATIONAL JOURNAL OF CANCER
    
    G. Pizza et al., "Immunotherapy of metastatic kidney cancer", INT J CANC, 94(1), 2001, pp. 109-120
48. Buzio, C; Andrulli, S; Santi, R; Pavone, L; Passalacqua, R; Potenzoni, D; Ferrozzi, F; Giacosa, R; Vaglio, A
    Long-term immunotherapy with low-dose interleukin-2 and interferon-alpha in the treatment of patients with advanced renal cell carcinoma
    CANCER
    
    C. Buzio et al., "Long-term immunotherapy with low-dose interleukin-2 and interferon-alpha in the treatment of patients with advanced renal cell carcinoma", CANCER, 92(9), 2001, pp. 2286-2296
49. Bay, JO; Choufi, B; Tournilhac, O; Faucher, C; Blaise, D
    Allogeneic hematopoietic cell transplantation in solid tumors
    BULLETIN DU CANCER
    
    J.O. Bay et al., "Allogeneic hematopoietic cell transplantation in solid tumors", B CANCER, 88(9), 2001, pp. 900-907
50. Ravaud, A
    Cell therapy for solid tumors
    BULLETIN DU CANCER
    
    A. Ravaud, "Cell therapy for solid tumors", B CANCER, 88(1), 2001, pp. 91-100
51. Melder, RJ; Kristensen, CA; Munn, LL; Jain, RK
    Modulation of A-NK cell rigidity: In vitro characterization and in vivo implications for cell delivery
    BIORHEOLOGY
    
    R.J. Melder et al., "Modulation of A-NK cell rigidity: In vitro characterization and in vivo implications for cell delivery", BIORHEOLOGY, 38(2-3), 2001, pp. 151-159
52. Alileche, A; Goldman, CK; Waldmann, TA
    Differential effects of IL-2 and IL-15 on expression of IL-2 receptor alpha
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
    
    A. Alileche et al., "Differential effects of IL-2 and IL-15 on expression of IL-2 receptor alpha", BIOC BIOP R, 285(5), 2001, pp. 1302-1308
53. Boni, LT; Batenjany, MM; Neville, ME; Guo, YQ; Xu, L; Wu, FJ; Mason, JT; Robb, RJ; Popescu, MC
    Interleukin-2-induced small unilamellar vesicle coalescence
    BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES
    
    L.T. Boni et al., "Interleukin-2-induced small unilamellar vesicle coalescence", BBA-BIOMEMB, 1514(1), 2001, pp. 127-138
54. Braun, SW; Gerhartz, HH; Schmetzer, HM
    Influence of cytokines and autologous lymphokine-activated killer cells onleukemic bone marrow cells and colonies in AML
    ACTA HAEMATOLOGICA
    
    S.W. Braun et al., "Influence of cytokines and autologous lymphokine-activated killer cells onleukemic bone marrow cells and colonies in AML", ACT HAEMAT, 105(4), 2001, pp. 209-221
55. Marroquin, CE; White, DE; Steinberg, SM; Rosenberg, SA; Schwartzentruber, DJ
    Decreased tolerance to interleukin-2 with repeated courses of therapy in patients with metastatic melanoma or renal cell cancer
    JOURNAL OF IMMUNOTHERAPY
    
    C.E. Marroquin et al., "Decreased tolerance to interleukin-2 with repeated courses of therapy in patients with metastatic melanoma or renal cell cancer", J IMMUNOTH, 23(3), 2000, pp. 387-392
56. Fischer, B; Muller, B; Fisch, P; Kreutz, W
    An acidic microenvironment inhibits antitumoral non-major histocompatibility complex-restricted cytotoxicity: Implications for cancer immunotherapy
    JOURNAL OF IMMUNOTHERAPY
    
    B. Fischer et al., "An acidic microenvironment inhibits antitumoral non-major histocompatibility complex-restricted cytotoxicity: Implications for cancer immunotherapy", J IMMUNOTH, 23(2), 2000, pp. 196-207
57. deMagalhaes-Silverman, M; Donnenberg, A; Lembersky, B; Elder, E; Lister, J; Rybka, W; Whiteside, T; Ball, E
    Posttransplant adoptive immunotherapy with activated natural killer cells in patients with metastatic breast cancer
    JOURNAL OF IMMUNOTHERAPY
    
    M. deMagalhaes-Silverman et al., "Posttransplant adoptive immunotherapy with activated natural killer cells in patients with metastatic breast cancer", J IMMUNOTH, 23(1), 2000, pp. 154-160
58. Lee, JH; Klein, HG
    From leukocyte reduction to leukocyte transfusion: the immunological effects of transfused leukocytes
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
    
    J.H. Lee e H.G. Klein, "From leukocyte reduction to leukocyte transfusion: the immunological effects of transfused leukocytes", BEST P R C, 13(4), 2000, pp. 585-600
59. Tio, RA; Nieken, J; de Vries, EGE; Pfeiffer, C; de Jongste, MJL; Pieper, E; Moshage, H; Limburg, PC; Mulder, NH
    Negative inotropic effects of recombinant interleukin 2 in patients without left ventricular dysfunction
    EUROPEAN JOURNAL OF HEART FAILURE
    
    R.A. Tio et al., "Negative inotropic effects of recombinant interleukin 2 in patients without left ventricular dysfunction", EUR J HE FA, 2(2), 2000, pp. 167-173
60. Tagawa, M
    Cytokine therapy for cancer
    CURRENT PHARMACEUTICAL DESIGN
    
    M. Tagawa, "Cytokine therapy for cancer", CUR PHARM D, 6(6), 2000, pp. 681-699
61. Mekhail, T; Wood, L; Bukowski, R
    Interleukin-2 in cancer therapy - Uses and optimum management of adverse effects
    BIODRUGS
    
    T. Mekhail et al., "Interleukin-2 in cancer therapy - Uses and optimum management of adverse effects", BIODRUGS, 14(5), 2000, pp. 299-318
62. Lehours, P; Raher, S; Dubois, S; Guo, J; Godard, A; Jacques, Y
    Subunit structure of the high and low affinity human interleukin-15 receptors
    EUROPEAN CYTOKINE NETWORK
    
    P. Lehours et al., "Subunit structure of the high and low affinity human interleukin-15 receptors", EUR CYTOKIN, 11(2), 2000, pp. 207-215
63. Blaise, D; Attal, M; Reiffers, J; Michallet, M; Bellanger, C; Pico, JL; Stoppa, AM; Payen, C; Marit, G; Bouabdallah, R; Sotto, JJ; Rossi, JF; Brandely, M; Hercend, T; Maraninchi, D
    Randomized study of recombinant interleukin-2 after autologous bone marrowtransplantation for acute leukemia in first complete remission
    EUROPEAN CYTOKINE NETWORK
    
    D. Blaise et al., "Randomized study of recombinant interleukin-2 after autologous bone marrowtransplantation for acute leukemia in first complete remission", EUR CYTOKIN, 11(1), 2000, pp. 91-97
64. Frost, P; Bonavida, B
    Circumvention of tumor cell escape following specific immunotherapy
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
    
    P. Frost e B. Bonavida, "Circumvention of tumor cell escape following specific immunotherapy", CANC BIO R, 15(2), 2000, pp. 141-152
65. Fisher, RI; Rosenberg, SA; Fyfe, G
    Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma
    CANCER JOURNAL FROM SCIENTIFIC AMERICAN
    
    R.I. Fisher et al., "Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma", CA J SCI AM, 6, 2000, pp. S55-S57
66. Vuky, J; Motzer, RJ
    Cytokine therapy in renal cell cancer
    UROLOGIC ONCOLOGY
    
    J. Vuky e R.J. Motzer, "Cytokine therapy in renal cell cancer", UROL ONCOL, 5(6), 2000, pp. 249-257
67. Visonneau, S; Cesano, A; Porter, DL; Luger, SL; Schuchter, L; Kamoun, M; Torosian, MH; Duffy, K; Sickles, C; Stadtmauer, EA; Santoli, D
    Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer
    CLINICAL CANCER RESEARCH
    
    S. Visonneau et al., "Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer", CLIN CANC R, 6(5), 2000, pp. 1744-1754
68. Kaplan, B; Moy, RL
    Effect of perilesional injections of PEG-interleukin-2 on basal cell carcinoma
    DERMATOLOGIC SURGERY
    
    B. Kaplan e R.L. Moy, "Effect of perilesional injections of PEG-interleukin-2 on basal cell carcinoma", DERM SURG, 26(11), 2000, pp. 1037-1040
69. Bohle, A; Thanhauser, A; Ernst, M; Flad, HD; Rusch-Gerdes, S; Jocham, D; Ulmer, AJ
    Reduction of side effects of intravesical therapy with bacille Calmette-Guerin by pentoxifylline? An in vitro approach
    CLINICAL INFECTIOUS DISEASES
    
    A. Bohle et al., "Reduction of side effects of intravesical therapy with bacille Calmette-Guerin by pentoxifylline? An in vitro approach", CLIN INF D, 31, 2000, pp. S101-S105
70. Knupfer, MM; Knupfer, H; Van Gool, S; Domula, M; Wolff, JEA
    Interferon gamma inhibits proliferation and hyaluronic acid adhesion of human malignant glioma cells in vitro
    CYTOKINE
    
    M.M. Knupfer et al., "Interferon gamma inhibits proliferation and hyaluronic acid adhesion of human malignant glioma cells in vitro", CYTOKINE, 12(4), 2000, pp. 409-412
71. Cohen, PA; Peng, LM; Plautz, GE; Kim, JA; Weng, DE; Shu, SY
    CD4(+) T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection
    CRITICAL REVIEWS IN IMMUNOLOGY
    
    P.A. Cohen et al., "CD4(+) T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection", CR R IMMUN, 20(1), 2000, pp. 17-56
72. Toge, T; Yamaguchi, Y
    Protein-bound polysaccharide increases survival in resected gastric cancercases stratified with a preoperative granulocyte and lymphocyte count
    ONCOLOGY REPORTS
    
    T. Toge e Y. Yamaguchi, "Protein-bound polysaccharide increases survival in resected gastric cancercases stratified with a preoperative granulocyte and lymphocyte count", ONCOL REP, 7(5), 2000, pp. 1157-1161
73. Suzuki, M; Kimura, H; Iwai, N; Fujisawa, T
    Intermittent adjuvant chemo-immunotherapy after resection of non-small cell lung cancer with multilevel mediastinal lymph node metastasis
    ONCOLOGY REPORTS
    
    M. Suzuki et al., "Intermittent adjuvant chemo-immunotherapy after resection of non-small cell lung cancer with multilevel mediastinal lymph node metastasis", ONCOL REP, 7(3), 2000, pp. 545-549
74. Huang, GTJ; Zhang, XL; Park, NH
    Increased ICAM-1 expression in transformed human oral epithelial cells: molecular mechanism and functional role in peripheral blood mononuclear cell adhesion and lymphokine-activated-killer cell cytotoxicity
    INTERNATIONAL JOURNAL OF ONCOLOGY
    
    G.T.J. Huang et al., "Increased ICAM-1 expression in transformed human oral epithelial cells: molecular mechanism and functional role in peripheral blood mononuclear cell adhesion and lymphokine-activated-killer cell cytotoxicity", INT J ONCOL, 17(3), 2000, pp. 479-486
75. Schendel, DJ; Falk, CS; Nossner, E; Maget, B; Kressenstein, S; Urlinger, S; Tampe, R; Gansbacher, B
    Gene transfer of human interferon gamma complementary DNA into a renal cell carcinoma line enhances MHC-restricted cytotoxic T lymphocyte recognitionbut suppresses non-MHC-restricted effector cell activity
    GENE THERAPY
    
    D.J. Schendel et al., "Gene transfer of human interferon gamma complementary DNA into a renal cell carcinoma line enhances MHC-restricted cytotoxic T lymphocyte recognitionbut suppresses non-MHC-restricted effector cell activity", GENE THER, 7(11), 2000, pp. 950-959
76. Paciucci, PA; Ryder, JS; Mandeli, JP; Morris, JC; Holland, JF
    Interleukin-2 plus chemotherapy for patients with metastatic melanoma
    MELANOMA RESEARCH
    
    P.A. Paciucci et al., "Interleukin-2 plus chemotherapy for patients with metastatic melanoma", MELANOMA RE, 10(3), 2000, pp. 291-295
77. Bernengo, MG; Quaglino, P; Cappello, N; Lisa, F; Osella-Abate, S; Fierro, MT
    Macrophage-mediated immunostimulation modulates therapeutic efficacy of interleukin-2 based chemoimmunotherapy in advanced metastatic melanoma patients
    MELANOMA RESEARCH
    
    M.G. Bernengo et al., "Macrophage-mediated immunostimulation modulates therapeutic efficacy of interleukin-2 based chemoimmunotherapy in advanced metastatic melanoma patients", MELANOMA RE, 10(1), 2000, pp. 55-65
78. Skubitz, KM; Anderson, PM
    Inhalational interleukin-2 liposomes for pulmonary metastases: a phase I clinical trial
    ANTI-CANCER DRUGS
    
    K.M. Skubitz e P.M. Anderson, "Inhalational interleukin-2 liposomes for pulmonary metastases: a phase I clinical trial", ANTI-CANC D, 11(7), 2000, pp. 555-563
79. Moller, P; Moller, H; Sun, YS; Dorbic, T; Henz, BM; Wittig, B; Schadendorf, D
    Increased non-major histocompatibility complex-restricted lytic activity in melanoma patients vaccinated with cytokine gene-transfected autologous tumor cells
    CANCER GENE THERAPY
    
    P. Moller et al., "Increased non-major histocompatibility complex-restricted lytic activity in melanoma patients vaccinated with cytokine gene-transfected autologous tumor cells", CANC GENE T, 7(7), 2000, pp. 976-984
80. Thiele, J; Kvasnicka, HM; Schmitt-Graeff, A
    Therapy-related changes of CD20(+) and CD45RO(+) lymphocyte subsets in chronic myeloid leukemia (CML): An immunohistochemical and morphometric study on sequential trephine biopsies of the bone marrow
    MODERN PATHOLOGY
    
    J. Thiele et al., "Therapy-related changes of CD20(+) and CD45RO(+) lymphocyte subsets in chronic myeloid leukemia (CML): An immunohistochemical and morphometric study on sequential trephine biopsies of the bone marrow", MOD PATHOL, 13(8), 2000, pp. 888-896
81. Yaniv, I
    Lymphokines post autologous peripheral blood stem cell transplantation in children
    PEDIATRIC HEMATOLOGY AND ONCOLOGY
    
    I. Yaniv, "Lymphokines post autologous peripheral blood stem cell transplantation in children", PED HEM ONC, 17(1), 2000, pp. 9-13
82. Vlk, V; Eckschlager, T; Kavan, P; Kabickova, E; Koutecky, J; Sobota, V; Bubenik, J; Pospisilova, D
    Clinical ineffectiveness of IL-2 and/or IFN alpha administration after autologous PBSC transplantation in pediatric oncological patients
    PEDIATRIC HEMATOLOGY AND ONCOLOGY
    
    V. Vlk et al., "Clinical ineffectiveness of IL-2 and/or IFN alpha administration after autologous PBSC transplantation in pediatric oncological patients", PED HEM ONC, 17(1), 2000, pp. 31-44
83. To, WC; Wood, BG; Krauss, JC; Strome, M; Esclamado, RM; Lavertu, P; Dasko, D; Kim, JA; Plautz, GE; Leff, BE; Smith, V; Sandstrom-Wakeling, K; Shu, SY
    Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck - A phase 1 study
    ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY
    
    W.C. To et al., "Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck - A phase 1 study", ARCH OTOLAR, 126(10), 2000, pp. 1225-1231
84. Weynants, P
    Immunity and lung cancer: perspectives for an antitumor vaccine
    REVUE DES MALADIES RESPIRATOIRES
    
    P. Weynants, "Immunity and lung cancer: perspectives for an antitumor vaccine", REV MAL RES, 17(1), 2000, pp. 371-380
85. Fong, TC; Sauter, SL; Ibanez, CE; Sheridan, PL; Jolly, DJ
    The use and development of retroviral vectors to deliver cytokine genes for cancer therapy
    CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS
    
    T.C. Fong et al., "The use and development of retroviral vectors to deliver cytokine genes for cancer therapy", CR R THER, 17(1), 2000, pp. 1-60
86. Motzer, RJ; Mazumdar, M; Bacik, J; Russo, P; Berg, WJ; Metz, EM
    Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma
    JOURNAL OF CLINICAL ONCOLOGY
    
    R.J. Motzer et al., "Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma", J CL ONCOL, 18(9), 2000, pp. 1928-1935
87. Lindsey, KR; Rosenberg, SA; Sherry, RM
    Impact of the number of treatment courses on the clinical response of patients who receive high-dose bolus interleukin-2
    JOURNAL OF CLINICAL ONCOLOGY
    
    K.R. Lindsey et al., "Impact of the number of treatment courses on the clinical response of patients who receive high-dose bolus interleukin-2", J CL ONCOL, 18(9), 2000, pp. 1954-1959
88. Capuron, L; Ravaud, A; Dantzer, R
    Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy
    JOURNAL OF CLINICAL ONCOLOGY
    
    L. Capuron et al., "Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy", J CL ONCOL, 18(10), 2000, pp. 2143-2151
89. Sashchenko, LP; Dukhanina, EA; Ioudinkova, ES; Iarovaia, OV; Lukianova, TI; Kabanova, OD; Gnuchev, NV; Razin, SV
    Nonlymphoid cultured cells possess a system controlling cellular compatibility
    JOURNAL OF CELLULAR BIOCHEMISTRY
    
    L.P. Sashchenko et al., "Nonlymphoid cultured cells possess a system controlling cellular compatibility", J CELL BIOC, 78(2), 2000, pp. 186-196
90. Verma, V; Sharma, V; Shrivastava, SK; Nadkarni, JJ
    IL-12 acid IL-2 potentiate the in vitro tumor-specific activity of peripheral blood cells from cervical cancer patients
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
    
    V. Verma et al., "IL-12 acid IL-2 potentiate the in vitro tumor-specific activity of peripheral blood cells from cervical cancer patients", J EXP CL C, 19(3), 2000, pp. 367-374
91. Kawamura, A; Sekine, T; Sekiguchi, M; Yanoma, S; Kaneko, A; Haneda, T; Moriya, Y; Hayasaka, K; Kakizoe, T
    Six-year disease-free survival of a patient with metastatic eyelid squamous cell carcinoma and colon adenocarcinoma after repeated postoperative adoptive immunotherapy
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY
    
    A. Kawamura et al., "Six-year disease-free survival of a patient with metastatic eyelid squamous cell carcinoma and colon adenocarcinoma after repeated postoperative adoptive immunotherapy", JPN J CLIN, 30(6), 2000, pp. 267-271
92. Ueno, T; Ohtawa, K; Kimoto, Y; Sakurai, K; Kodera, Y; Hiroto, M; Matsushima, A; Nishimura, H; Inada, Y
    Polyethylene glycol-modified concanavalin A as an effective agent to stimulate anti-tumor cytotoxicity
    CANCER DETECTION AND PREVENTION
    
    T. Ueno et al., "Polyethylene glycol-modified concanavalin A as an effective agent to stimulate anti-tumor cytotoxicity", CANCER DET, 24(1), 2000, pp. 100-106
93. Thomas, ML; Samant, UC; Deshpande, RK; Chiplunkar, SV
    gamma delta T cells lyse autologous and allogenic oesophageal tumours: involvement of heat-shock proteins in the tumour cell lysis
    CANCER IMMUNOLOGY IMMUNOTHERAPY
    
    M.L. Thomas et al., "gamma delta T cells lyse autologous and allogenic oesophageal tumours: involvement of heat-shock proteins in the tumour cell lysis", CANCER IMMU, 48(11), 2000, pp. 653-659
94. Vasey, PA
    Immunotherapy for renal carcinoma: theoretical basis and current standard of care
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    
    P.A. Vasey, "Immunotherapy for renal carcinoma: theoretical basis and current standard of care", BR J CL PH, 50(6), 2000, pp. 521-529
95. Bohle, A
    BCG's mechanism of action - Increasing our understanding
    EUROPEAN UROLOGY
    
    A. Bohle, "BCG's mechanism of action - Increasing our understanding", EUR UROL, 37, 2000, pp. 1-8
96. Rohde, D; Wiesner, C; Graf, D; Wolff, J; Fuzesi, L; Jakse, G
    Interstitial fluid pressure is increased in renal cell carcinoma xenografts
    UROLOGICAL RESEARCH
    
    D. Rohde et al., "Interstitial fluid pressure is increased in renal cell carcinoma xenografts", UROL RES, 28(1), 2000, pp. 1-5
97. Oleksowicz, L; Escott, P; Leichman, GC; Spangenthal, E
    Sustained ventricular tachycardia and its successful prophylaxis during high-dose bolus interleukin-2 therapy for metastatic renal cell carcinoma
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
    
    L. Oleksowicz et al., "Sustained ventricular tachycardia and its successful prophylaxis during high-dose bolus interleukin-2 therapy for metastatic renal cell carcinoma", AM J CL ONC, 23(1), 2000, pp. 34-36
98. Gravis, G; Viens, P; Vey, N; Blaise, D; Stoppa, AM; Olive, D; Maraninchi, D
    Pilot study of immunotherapy with interleukin-2 after autologous stem celltransplantation in advanced breast cancers
    ANTICANCER RESEARCH
    
    G. Gravis et al., "Pilot study of immunotherapy with interleukin-2 after autologous stem celltransplantation in advanced breast cancers", ANTICANC R, 20(5C), 2000, pp. 3987-3991
99. Nio, Y; Hirahara, N; Minari, Y; Iguchi, C; Yamasawa, K; Toga, T; Tamura, K
    Induction of tumor-specific antitumor immunity after chemotherapy with cisplatin in mice bearing MOPC-104E plasmacytoma by modulation of MHC expression on tumor surface
    ANTICANCER RESEARCH
    
    Y. Nio et al., "Induction of tumor-specific antitumor immunity after chemotherapy with cisplatin in mice bearing MOPC-104E plasmacytoma by modulation of MHC expression on tumor surface", ANTICANC R, 20(5A), 2000, pp. 3293-3299
100. Bartholeyns, J; Bardot, V; Chokri, M; Romet-Lemonne, JL
     Adoptive immunotherapy: present status and perspectives in cancer treatment.
     REVUE DE MEDECINE INTERNE
     
     J. Bartholeyns et al., "Adoptive immunotherapy: present status and perspectives in cancer treatment.", REV MED IN, 21(10), 2000, pp. 863-871